Filing Flows › Cue Biopharma (CUE) › Stock forecast & fair value
Cue Biopharma (CUE) stock forecast and price target
Cue Biopharma (CUE) trades at $18.73. 3 analysts' median price target is $83.00 (+343%), from $66.00 to $115.00.
Cue Biopharma's latest quarter
Cue Biopharma, Q2 2026: revenue $7.9M (+167% year over year), net loss $153M, operating cash flow −$29.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for CUE stock?
The median of 3 analysts' 12-month targets is $83.00, +343% from $18.73; the range is $66.00 to $115.00. The average rating is none.
Does Cue Biopharma usually beat earnings estimates?
It beat the consensus EPS estimate in 67% of the quarters on record.
Is CUE stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.